20 May 2013
Keywords: abraxane, rights, cost, deepens, abraxis, loss, company
Article | 16 March 2009
US company Abraxis BioScience's loss deepened more than five-fold, year-on-year for 2008, on costs for the re-purchase of rights to lead
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
16 March 2009
17 May 2013
© 2013 thepharmaletter.com